Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Biomarin Pharmaceutical stock

Learn how to easily invest in Biomarin Pharmaceutical stock.

Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Biomarin Pharmaceutical employs 3,082 staff and has a trailing 12-month revenue of around $2.2 billion.

How to buy Biomarin Pharmaceutical stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BMRN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Biomarin Pharmaceutical stock price (NASDAQ: BMRN)

Use our graph to track the performance of BMRN stocks over time.

Biomarin Pharmaceutical shares at a glance

Information last updated 2023-09-19.
Latest market close$86.27
52-week range$80.53 - $117.77
50-day moving average $89.37
200-day moving average $96.88
Wall St. target price$117.18
PE ratio 170.8077
Dividend yield $0 (0%)
Earnings per share (TTM) $0.52

Buy Biomarin Pharmaceutical stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Finder Rating: 4.1 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Finder Rating: 4.2 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Biomarin Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biomarin Pharmaceutical price performance over time

Historical closes compared with the close of $86.27 from 2023-09-21

1 week (2023-09-15) -2.14%
1 month (2023-08-22) -4.71%
3 months (2023-06-22) -9.77%
6 months (2023-03-18) N/A
1 year (2022-09-22) 1.59%
2 years (2021-09-22) 9.16%
3 years (2020-09-22) 8.71%
5 years (2018-09-21) 97.84

Is Biomarin Pharmaceutical stock undervalued or overvalued?

Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biomarin Pharmaceutical financials

Revenue TTM $2.2 billion
Operating margin TTM 4.15%
Gross profit TTM $1.6 billion
Return on assets TTM 0.91%
Return on equity TTM 2.15%
Profit margin 4.47%
Book value $25.42
Market Capitalization $16.7 billion

TTM: trailing 12 months

Biomarin Pharmaceutical share dividends

We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.

Biomarin Pharmaceutical share price volatility

Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $80.53 up to $117.77. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.3607. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).

Biomarin Pharmaceutical overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U. S.

Frequently asked questions

What percentage of Biomarin Pharmaceutical is owned by insiders or institutions?
Currently 0.488% of Biomarin Pharmaceutical shares are held by insiders and 97.772% by institutions.
How many people work for Biomarin Pharmaceutical?
Latest data suggests 3,082 work at Biomarin Pharmaceutical.
When does the fiscal year end for Biomarin Pharmaceutical?
Biomarin Pharmaceutical's fiscal year ends in December.
Where is Biomarin Pharmaceutical based?
Biomarin Pharmaceutical's address is: 770 Lindaro Street, San Rafael, CA, United States, 94901
What is Biomarin Pharmaceutical's ISIN number?
Biomarin Pharmaceutical's international securities identification number is: US09061G1013
What is Biomarin Pharmaceutical's CUSIP number?
Biomarin Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 09061G101

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site